Effects Of Sitaxsentan On Proteinuria, 24-Hour Blood Pressure, And Arterial Stiffness In Chronic Kidney Disease Subjects 
      This study is being conducted to evaluate sitaxsentan dosing in subjects with chronic kidney
      disease.
     Chronic Kidney Disease :

          -  Has stage 1-5 chronic kidney disease (CKD) as defined by the Kidney Disease Outcomes
             Quality Initiative (K/DOQI) with proteinuria, including any of the following
             aetiologies: immunoglobulin (IgA) nephropathy, polycystic kidney disease (PCKD),
             congenital abnormalities, reflux nephropathy, focal segmental glomerulosclerosis,
             minimal change nephropathy, and membranous nephropathy.

         :

          -  Required peritoneal dialysis or haemodialysis.

          -  Has kidney disease due to diabetes mellitus, vasculitis, systemic lupus erythematosus,
             or known renovascular disease; antiglomerular basement membrane disease; or is on
             immunosuppressive medication.
      